Navigation Links
Exenatide Once Monthly Showed Positive Results in Phase 2 Study
Date:3/10/2011

emic control," said Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals. "Based on the encouraging results of this study, we plan to proceed with regulatory interactions to outline the next steps for this important program."

More than 90 percent of patients overall completed the study. The most common adverse events among the exenatide once monthly treatment groups were headache and nausea. Headache and diarrhea were most common among the once-weekly BYDUREON group. No major or minor hypoglycemia was reported in the study.

Exenatide once monthly is a new, extended-release formulation of exenatide, the active ingredient in BYETTA® (exenatide) injection, which is given twice daily. Exenatide once monthly is based on the same Medisorb® microsphere technology used in BYDUREON.

Study Design

This phase 2, randomized, open-label study included 121 adults with type 2 diabetes who were not achieving adequate glucose control using diet and exercise alone or with a stable regimen of metformin, Actos® (pioglitazone), or both.  Subjects were randomized to receive either 2 mg weekly subcutaneous injections of BYDUREON or subcutaneous injections of exenatide once monthly at a low, medium or high dose, each administered once every four weeks, for a total of 20 weeks.

About Diabetes

Diabetes affects nearly 26 million people in the U.S. and an estimated 285 million adults worldwide.(i, ii)  Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes costs approximately $174 billion per year in direct and indirect medical expenses.(iii)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
3. Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
4. Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
5. New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
6. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
7. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
8. Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
9. BioProcess International Launches Monthly Asia-Pacific eNewsletter
10. Technology PR Boutique Launches PRTechConnect to Help Tech Startups Restart Economy with Industry's First $999 Monthly Service
11. RSB Spine, LLC, Announces Record Second-Quarter 2010 Revenue and Monthly Sales Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  Tikcro Technologies Ltd. (OTCQB: ... to continue trading on OTCQB  Marketplace, the market ... Marketplace allows for a continuous public market for ... have real-time quotes and market information on us ... OTCQB Marketplace includes U.S. and international companies in ...
(Date:5/5/2015)... ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: ... and Chief Executive Officer, will present live at ... May 7, 2015     TIME:  11:30 am ET/8:30 am ... the red "register/ watch presentations" button ... where investors are invited to ask the company ...
(Date:5/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services ... Global Version" report to their offering. ... of molecular diagnostics and pharmacogenics hold the promise ... that is moving out of the national and ...
(Date:5/5/2015)...   Tocagen Inc. , a clinical-stage immuno-oncology ... , M.D., a venture partner at New Enterprise ... of directors of Tocagen. Dr. Parkinson has more ... development, including leading clinical activities at Amgen and ... cancer therapeutics Gleevec®, Femara®, Zometa®, Kepivance® and Vectibix®, ...
Breaking Biology Technology:Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4
... physicians and scientists from institutions around the world such ... Control and the National Institutes of Health will meet ... Hygienes Annual Meeting on Nov. 4-8, in Philadelphia to ... and global health threats. , Highlights include: , ...
... (Nasdaq: HGSI ) today announced that it will ... the quarter ended,September 30, 2007. These results are expected ... http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) The conference call will be ... November 1, 2007, at 11:00 am Eastern Time. ...
... PITTSBURGH, Oct. 24 The Pittsburgh Life ... region,s life,sciences industry on a fast track ... $115,000 in Innovention Technologies, LLC, a developmental-stage,medical ... and commercialize a,highly-maneuverable surgical probe that will ...
Cached Biology Technology:Specialists in infectious disease and global health convene at Philadelphia meeting 2Human Genome Sciences To Sponsor Conference Call To Discuss Third Quarter 2007 Financial Results 2The PLSG Invests $115,000 in Innovention Technologies, LLC 2
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... and human health effects from disposal of millions of ... recommend stronger government policies to encourage recovery, recycling and ... of a new paper in the ACS journal ... and colleagues point out that Li-ion batteries have become ...
... Early screening for prostate cancer could become as easy for ... UC Irvine research published today in the Journal of ... decade of work, UC Irvine chemists have created a way ... urine, meaning that the disease could be detected far sooner, ...
... a "patient monitoring" device attached to a whale entangled ... how fishing lines changed a whale,s diving and swimming ... ability to eat and migrate, depletes their energy as ... result in a slow death. The scientists in ...
Cached Biology News:UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3
... contains choice of Printing Surface (3 glass slides coated ... layer, 1 silicon wafer coated with 1000 Angstroms of ... slides), PDMS Stamps (3 PDMS micropatterned stamps with series ... x 10 mm or 200 um x 10 mm ...
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
...
ECE-1 (H-60)...
Biology Products: